Cerus Zhongbaokang Shandong Biomedical Co News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cerus Corporation Announces Third Quarter 2023 Financial Results

02.11.2023 - Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million .

United statesNet loss attributable to cerus corporationCerus corporationCerus zhongbaokang shandong biomedical coCanadian blood servicesCerus corporation stockExchange commissionLoss attributableInvestor relationsReduced cryoprecipitated fibrinogen complexBiologics license applicationsBlood cellCeru quarterlyAccepted accounting principlesCalculated numberTreatable platelet

Cerus Corporation Announces Second Quarter 2023 Financial Results

Cerus Corporation Announces Second Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJessica hanoverNet loss attributable to cerus corporationCerus corporationExchange commissionWhile the companyCorporate affairsCerus corporation nasdaqUs department of defenseCerus zhongbaokang shandong biomedical coBlood cellsDutch medicines evaluation boardDevice regulationBlood cellRed blood cellsLoss attributable

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJoel trujilloExchange commissionCerus zhongbaokang shandong biomedical coCerus corporationNet loss attributable to cerus corporationCerus corporation nasdaqWall streetRevenue growth drivenRevenue guidance rangeRed blood cellsBlood cellLoss attributableInvestor relationsBiologics license applicationsCeru quarterly report